Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review

Pneumocystis Jirovecii Pneumonia after Initiation of Tofacitinib Therapy in Rheumatoid Arthritis: Case-Based Review

The use of biologic and targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARDs) in rheumatic diseases is constantly increasing during the last decade. Tofacitinib is a new oral Janus Kinase (JAK) inhibitor, approved for rheumatoid arthritis (RA), psoriatic arthritis and ulcerative colit...

Full description

Bibliographic Details
Main Authors: Ioannis Grigoropoulos, Konstantinos Thomas, Panagiotis Christoforou, Iliana Fanidi, Maria Papavdi, Fani Kyriakou, Melanie Deutsch, Maria Pirounaki, Dimitrios Vassilopoulos
Format: Article
Language:English
Published: PCO Convin S.A. 2019-01-01
Series:Mediterranean Journal of Rheumatology
Subjects:
rheumatoid arthritis
tofacitinib
Pneumocystis jirovecii
pneumonia
Online Access:http://www.mjrheum.org/assets/files/792/file189_735.pdf

Internet

http://www.mjrheum.org/assets/files/792/file189_735.pdf

Similar Items